>RDEA – They are also testing 806 (phase-2a) in gout syndrome because it showed reduction of uric acid in healthy people…<
RDEA806 will be dropped as a treatment for gout in favor of RDEA594 as soon as the phase-2a study in progress is completed. 594 is a metabolite of 806 that has no antiviral activity; it will presumably have a better safety and tolerability profile.
>…but I can't figure out the mechanism.<
The MoA in gout is blocking the URAT1 transporter.
Market Data 
Markets 
AI
